Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration
Saurav Brahmachari, … , Ted M. Dawson, Han Seok Ko
Saurav Brahmachari, … , Ted M. Dawson, Han Seok Ko
Published June 27, 2016
Citation Information: J Clin Invest. 2016;126(8):2970-2988. https://doi.org/10.1172/JCI85456.
View: Text | PDF
Research Article Neuroscience Article has an altmetric score of 490

Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration

  • Text
  • PDF
Abstract

Aggregation of α-synuclein contributes to the formation of Lewy bodies and neurites, the pathologic hallmarks of Parkinson disease (PD) and α-synucleinopathies. Although a number of human mutations have been identified in familial PD, the mechanisms that promote α-synuclein accumulation and toxicity are poorly understood. Here, we report that hyperactivity of the nonreceptor tyrosine kinase c-Abl critically regulates α-synuclein–induced neuropathology. In mice expressing a human α-synucleinopathy–associated mutation (hA53Tα-syn mice), deletion of the gene encoding c-Abl reduced α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Conversely, overexpression of constitutively active c-Abl in hA53Tα-syn mice accelerated α-synuclein aggregation, neuropathology, and neurobehavioral deficits. Moreover, c-Abl activation led to an age-dependent increase in phosphotyrosine 39 α-synuclein. In human postmortem samples, there was an accumulation of phosphotyrosine 39 α-synuclein in brain tissues and Lewy bodies of PD patients compared with age-matched controls. Furthermore, in vitro studies show that c-Abl phosphorylation of α-synuclein at tyrosine 39 enhances α-synuclein aggregation. Taken together, this work establishes a critical role for c-Abl in α-synuclein–induced neurodegeneration and demonstrates that selective inhibition of c-Abl may be neuroprotective. This study further indicates that phosphotyrosine 39 α-synuclein is a potential disease indicator for PD and related α-synucleinopathies.

Authors

Saurav Brahmachari, Preston Ge, Su Hyun Lee, Donghoon Kim, Senthilkumar S. Karuppagounder, Manoj Kumar, Xiaobo Mao, Joo Ho Shin, Yunjong Lee, Olga Pletnikova, Juan C. Troncoso, Valina L. Dawson, Ted M. Dawson, Han Seok Ko

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2009 Total
Citations: 7 10 11 17 13 14 10 10 9 2 1 104
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article (104)

Title and authors Publication Year
Preclinical studies and transcriptome analysis in a model of Parkinson’s disease with dopaminergic ZNF746 expression
Kim JH, Yang S, Kim H, Vo DK, Maeng HJ, Jo A, Shin JH, Shin JH, Baek HM, Lee GH, Kim SH, Lim KH, Dawson VL, Dawson TM, Joo JY, Lee Y
Molecular Neurodegeneration 2025
Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor Deficits
Kim Y, Vaidya B, McInnes J, Zoghbi HY
eNeuro 2025
Drug Repositioning and Repurposing for Disease-Modifying Effects in Parkinson's Disease.
Jeong SH, Lee PH
Journal of movement disorders 2025
Molecular mechanisms and consequences of TDP-43 phosphorylation in neurodegeneration.
Kellett EA, Bademosi AT, Walker AK
Molecular neurodegeneration 2025
Nonreceptor tyrosine kinase ABL1 regulates lysosomal acidification by phosphorylating the ATP6V1B2 subunit of the vacuolar-type H(+)-ATPase.
Song C, Dong Q, Yao Y, Cui Y, Zhang C, Lin L, Zhu L, Hu Y, Liu H, Jin Y, Li P, Liu X, Cao C
Autophagy 2025
Neuroprotective and Anti-Inflammatory Activity of Undaria pinnatifida Fucoidan In Vivo—A Proteomic Investigation
Yang C, Dwan C, Wimmer BC, Ronci M, Wilson R, Johnson L, Caruso V
Marine Drugs 2025
Genetic Code Expansion and Enzymatic Modifications as Accessible Methods for Studying Site-Specific Post-Translational Modifications of Alpha-Synuclein and Tau
Saleh IG, Shimogawa M, Ramirez J, Abakah B, Venkatesh Y, James HP, Li MH, Louie SA, Lougee MG, Chia WK, Cooley RB, Mehl RA, Baumgart T, Mach RH, Eliezer D, Rhoades E, Petersson EJ
bioRxiv 2025
Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease
Ratan Y, Rajput A, Pareek A, Pareek A, Jain V, Sonia S, Farooqui Z, Kaur R, Singh G
Biomolecules 2024
The identification of c-Abl inhibitors as potential agents for Parkinson's disease: a preliminary in silico approach.
Rymbai E, Roy D, Jupudi S, Srinivasadesikan V
Molecular Diversity 2024
A Phase I, Randomized, SAD, MAD, and PK Study of Risvodetinib in Older Adults and Parkinson's Disease.
Werner MH, Olanow CW, McGarry A, Meyer C, Kruger S, Klint C, Pellecchia J, Walaker S, Ereshefsky L, Blob L, Hassman H, Rodriguez C, Samara E, Safirstein B, Ellenbogen A
Journal of Parkinson's disease 2024
Phosphorylation and O-GlcNAcylation at the same α-synuclein site generate distinct fibril structures.
Hu J, Xia W, Zeng S, Lim YJ, Tao Y, Sun Y, Zhao L, Wang H, Le W, Li D, Zhang S, Liu C, Li YM
Nature Communications 2024
Glutamate Receptors and C-ABL Inhibitors: A New Therapeutic Approach for Parkinson's Disease.
Shejul PP, Doshi GM
Central nervous system agents in medicinal chemistry 2024
AN UPDATE ON MULTIPLE SYSTEM ATROPHY
Stankovic I, Kuijpers M, Kaufmann H
Current Opinion in Neurology 2024
Protein modification in neurodegenerative diseases
Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A
MedComm 2024
Posttranslational Modifications of α-Synuclein, Their Therapeutic Potential, and Crosstalk in Health and Neurodegenerative Diseases
Hassanzadeh K, Liu J, Maddila S, Mouradian MM
Pharmacological Reviews 2024
Dual inhibition of aminoacyl-tRNA synthetase interacting multifunctional protein-2 and α-synuclein by steroid derivative is neuroprotective in Parkinson's model.
Shin JY, Ha MW, Kim JH, Cheon J, Lee GH, Paek SM, Lee Y
iScience 2024
α-Synuclein pathology as a target in neurodegenerative diseases.
Park H, Kam TI, Dawson VL, Dawson TM
Nature reviews. Neurology 2024
Post-translational modifications of soluble α-synuclein regulate the amplification of pathological α-synuclein
Zhang S, Zhu R, Pan B, Xu H, Olufemi MF, Gathagan RJ, Li Y, Zhang L, Zhang J, Xiang W, Kagan EM, Cao X, Yuan C, Kim SJ, Williams CK, Magaki S, Vinters HV, Lashuel HA, Garcia BA, Petersson EJ, Trojanowski JQ, Lee VM, Peng C
Nature Neuroscience 2023
The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems
Nakmode DD, Day CM, Song Y, Garg S
Pharmaceutics 2023
Alpha synuclein post translational modifications: potential targets for Parkinson’s disease therapy?
Brembati V, Faustini G, Longhena F, Bellucci A
Frontiers in molecular neuroscience 2023
α-Synuclein oligomers and fibrils: partners in crime in synucleinopathies
Bigi A, Cascella R, Cecchi C
Neural Regeneration Research 2023
The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies
Motaln H, Rogelj B
Cells 2023
The Bidirectional Interplay of α-Synuclein with Lipids in the Central Nervous System and Its Implications for the Pathogenesis of Parkinson’s Disease
Battis K, Xiang W, Winkler J
International journal of molecular sciences 2023
Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson’s disease in rodent brains
Bérard M, Martínez-Drudis L, Sheta R, El-Agnaf OM, Oueslati A
Molecular Neurodegeneration 2023
c-Abl Phosphorylates MFN2 to Regulate Mitochondrial Morphology in Cells under Endoplasmic Reticulum and Oxidative Stress, Impacting Cell Survival and Neurodegeneration
Martinez A, Lamaizon CM, Valls C, Llambi F, Leal N, Fitzgerald P, Guy C, Kamiński MM, Inestrosa NC, van Zundert B, Cancino GI, Dulcey AE, Zanlungo S, Marugan JJ, Hetz C, Green DR, Alvarez AR
Antioxidants 2023
Development and validation of an expanded antibody toolset that captures alpha-synuclein pathological diversity in Lewy body diseases
Altay MF, Kumar ST, Burtscher J, Jagannath S, Strand C, Miki Y, Parkkinen L, Holton JL, Lashuel HA
npj Parkinson's Disease 2023
Soluble alpha-synuclein post-translational modifications: unexpected regulators of pathological alpha-synuclein amplification
Kapila S, Sun Y, Peng C, Zhang S
Neural Regeneration Research 2023
Genetic modifiers of synucleinopathies—lessons from experimental models
Lee RM, Koh TW
2023
Emerging Therapeutic Strategies for Parkinson’s Disease and Future Prospects: A 2021 Update
N Gouda, A Elkamhawy, J Cho
Biomedicines 2022
Consequences of variability in α-synuclein fibril structure on strain biology
S Holec, S Liu, A Woerman
Acta Neuropathologica 2022
Emerging targets signaling for inflammation in Parkinson’s disease drug discovery
R Khairnar, N Parihar, K Prabhavalkar, L Bhatt
Metabolic Brain Disease 2022
Association of p53 with Neurodegeneration in Parkinson’s Disease
Q Luo, W Sun, Y Wang, J Li, D Li, E Tan
Parkinson's Disease 2022
Conformational strains of pathogenic amyloid proteins in neurodegenerative diseases
D Li, C Liu
Nature Reviews Neuroscience 2022
Phase-Separated Subcellular Compartmentation and Related Human Diseases
Zhang L, Wang S, Wang W, Shi J, Stovall DB, Li D, Sui G
International journal of molecular sciences 2022
Protein interaction networks in neurodegenerative diseases: From physiological function to aggregation
Calabrese G, Molzahn C, Mayor T
The Journal of biological chemistry 2022
Role of post-translational modifications on the alpha-synuclein aggregation-related pathogenesis of Parkinson’s disease
Yoo H, Lee J, Kim B, Moon H, Jeong H, Lee K, Song WJ, Hur JK, Oh Y
BMB Reports 2022
α-Synuclein fibril-specific nanobody reduces prion-like α-synuclein spreading in mice
Butler YR, Liu Y, Kumbhar R, Zhao P, Gadhave K, Wang N, Li Y, Mao X, Wang W
Nature Communications 2022
c-Abl kinase at the crossroads of healthy synaptic remodeling and synaptic dysfunction in neurodegenerative diseases
Gutiérrez DA, Chandía-Cristi A, Yáñez MJ, Zanlungo S, Álvarez AR
Neural Regeneration Research 2022
Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein
Ulamec SM, Maya-Martinez R, Byrd EJ, Dewison KM, Xu Y, Willis LF, Sobott F, Heath GR, van Oosten Hawle P, Buchman VL, Radford SE, Brockwell DJ
Nature Communications 2022
Rosmarinic Acid Attenuates Rotenone-Induced Neurotoxicity in SH-SY5Y Parkinson’s Disease Cell Model through Abl Inhibition
Han X, Han B, Zhao Y, Li G, Wang T, He J, Du W, Cao X, Gan J, Wang Z, Zheng W
Nutrients 2022
Nilotinib in Parkinson's disease: A systematic review and meta-analysis
Xie X, Yuan P, Kou L, Chen X, Li J, Li Y
Frontiers in aging neuroscience 2022
Roles for c-Abl in postoperative neurodegeneration.
Feng L, Fu S, Yao Y, Li Y, Xu L, Zhao Y, Luo L
International journal of medical sciences 2022
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson's Disease.
Patel J, Panicker N, Dawson VL, Dawson TM
CNS Drugs 2022
c-Abl Regulates the Pathological Deposition of TDP-43 via Tyrosine 43 Phosphorylation
Lee S, Ryu HG, Kweon SH, Kim H, Park H, Lee KH, Jang SM, Na CH, Kim S, Ko HS
Cells 2022
The c-Abl/p73 pathway induces neurodegeneration in a Parkinson's disease model
Marín T, Valls C, Jerez C, Huerta T, Elgueta D, Vidal RL, Alvarez AR, Cancino GI
2022
Lymphocyte Activation Gene 3 (Lag3) Contributes to α-Synucleinopathy in α-Synuclein Transgenic Mice
H Gu, X Yang, X Mao, E Xu, C Qi, H Wang, S Brahmachari, B York, M Sriparna, A Li, M Chang, P Patel, VL Dawson, TM Dawson
Frontiers in cellular neuroscience 2021
α-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism
S Ghosh, SJ Won, J Wang, R Fong, NJ Butler, A Moss, C Wong, J Pan, J Sanchez, A Huynh, L Wu, FP Manfredsson, RA Swanson
Progress in Neurobiology 2021
The cell biology of Parkinson’s disease
N Panicker, P Ge, VL Dawson, TM Dawson
The Journal of Cell Biology 2021
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
LM Oliveira, T Gasser, R Edwards, M Zweckstetter, R Melki, L Stefanis, HA Lashuel, D Sulzer, K Vekrellis, GM Halliday, JJ Tomlinson, M Schlossmacher, PH Jensen, J Schulze-Hentrich, O Riess, WD Hirst, O El-Agnaf, B Mollenhauer, P Lansbury, TF Outeiro
npj Parkinson's Disease 2021
Parkinson’s Disease Dementia: Synergistic Effects of Alpha-Synuclein, Tau, Beta-Amyloid, and Iron
J Han, Y Fan, P Wu, Z Huang, X Li, L Zhao, Y Ji, M Zhu
Frontiers in aging neuroscience 2021
Expanding the role of proteasome homeostasis in Parkinson’s disease: beyond protein breakdown
M Bi, X Du, Q Jiao, , H Jiang
Cell Death and Disease 2021
Preclinical Detection of Alpha-Synuclein Seeding Activity in the Colon of a Transgenic Mouse Model of Synucleinopathy by RT-QuIC
JY Han, C Shin, YP Choi
Viruses 2021
Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease
D Li, C Liu
Nature Chemical Biology 2021
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3β Survival Pathway
C Yan, H Yu, Y Liu, P Wu, C Wang, H Zhao, K Yang, Q Shao, Y Zhong, W Zhao, J Li, N Liu, J Di, C Li, L Bao, C Gao
Journal of Molecular Neuroscience 2021
Mechanistic basis for receptor-mediated pathological α-synuclein fibril cell-to-cell transmission in Parkinson's disease
S Zhang, YQ Liu, C Jia, YJ Lim, G Feng, E Xu, H Long, Y Kimura, Y Tao, C Zhao, C Wang, Z Liu, JJ Hu, MR Ma, Z Liu, L Jiang, D Li, R Wang, VL Dawson, TM Dawson, YM Li, X Mao, C Liu
Proceedings of the National Academy of Sciences 2021
Chemoenzymatic Semi‐synthesis Enables Efficient Production of Isotopically Labeled α‐Synuclein with Site‐Specific Tyrosine Phosphorylation
B Pan, JH Park, T Ramlall, D Eliezer, E Rhoades, EJ Petersson
Chembiochem : a European journal of chemical biology 2021
Parkin interacting substrate phosphorylation by c-Abl drives dopaminergic neurodegeneration
H Kim, J Shin, A Jo, J Kim, S Park, J Choi, H Kang, V Dawson, T Dawson, J Shin, Y Lee
Brain 2021
Parkinson's Disease Modification Through Abl Kinase Inhibition: An Opportunity
M Werner, C Olanow
Movement disorders : official journal of the Movement Disorder Society 2021
The dual role of c‐src in cell‐to‐cell transmission of α‐synuclein
YR Choi, JB Kim, SJ Kang, HR Noh, I Jou, EH Joe, SM Park
EMBO reports 2020
Clinically Precedented Protein Kinases: Rationale for Their Use in Neurodegenerative Disease
CL Benn, LA Dawson
Frontiers in aging neuroscience 2020
In Search of Effective Treatments Targeting α-Synuclein Toxicity in Synucleinopathies: Pros and Cons
M Fouka, P Mavroeidi, G Tsaka, M Xilouri
Frontiers in Cell and Developmental Biology 2020
SUMOylation in α-Synuclein Homeostasis and Pathology
M Savyon, S Engelender
Frontiers in aging neuroscience 2020
Approaches to Disease Modification for Parkinson’s Disease: Clinical Trials and Lessons Learned
AY Hung, MA Schwarzschild
Neurotherapeutics 2020
PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson’s disease
P Ge, VL Dawson, TM Dawson
Molecular Neurodegeneration 2020
Chemoenzymatic Semisynthesis of Phosphorylated α-Synuclein Enables Identification of a Bidirectional Effect on Fibril Formation
B Pan, E Rhoades, EJ Petersson
ACS chemical biology 2020
α-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment
R Karim, EE Liao, J Kim, J Meints, HM Martinez, O Pletnikova, JC Troncoso, MK Lee
Molecular Neurodegeneration 2020
Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid
CH Na, G Sathe, LS Rosenthal, AR Moghekar, VL Dawson, TM Dawson, A Pandey
Clinical Proteomics 2020
Parkinson’s disease-related phosphorylation at Tyr39 rearranges α-synuclein amyloid fibril structure revealed by cryo-EM
K Zhao, YJ Lim, Z Liu, H Long, Y Sun, JJ Hu, C Zhao, Y Tao, X Zhang, D Li, YM Li, C Liu
Proceedings of the National Academy of Sciences 2020
Current and emerging therapeutic targets for Parkinson’s disease
T Pingale, GL Gupta
Metabolic Brain Disease 2020
Keeping α-Synuclein at Bay: A More Active Role of Molecular Chaperones in Preventing Mitochondrial Interactions and Transition to Pathological States?
EE Aspholm, I Matečko-Burmann, BM Burmann
Life Sciences 2020
Looking Beyond the Core: The Role of Flanking Regions in the Aggregation of Amyloidogenic Peptides and Proteins
SM Ulamec, DJ Brockwell, SE Radford
Frontiers in neuroscience 2020
Amyloid-like oligomerization of AIMP2 contributes to α-synuclein interaction and Lewy-like inclusion
S Ham, SP Yun, H Kim, D Kim, BA Seo, H Kim, JY Shin, MA Dar, GH Lee, YI Lee, D Kim, S Kim, HS Kweon, JH Shin, HS Ko, Y Lee
Science Translational Medicine 2020
Oxidative stress in vagal neurons promotes Parkinsonian pathology and intercellular α-synuclein transfer
Ruth E Musgrove, Michael Helwig, Eun-Jin Bae, Helia Aboutalebi, Seung-Jae Lee, Ayse Ulusoy, Donato A. Di Monte
Journal of Clinical Investigation 2019
Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration
AJ Fowler, M Hebron, AA Missner, R Wang, X Gao, BT Kurd-Misto, X Liu, CE Moussa
Drugs in R & D 2019
Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
D Savitt, J Jankovic
Drugs 2019
Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity
D Hu, X Sun, X Liao, X Zhang, S Zarabi, A Schimmer, Y Hong, C Ford, Y Luo, X Qi
Acta Neuropathologica 2019
Felodipine induces autophagy in mouse brains with pharmacokinetics amenable to repurposing
FH Siddiqi, FM Menzies, A Lopez, E Stamatakou, C Karabiyik, R Ureshino, T Ricketts, M Jimenez-Sanchez, MA Esteban, L Lai, MD Tortorella, Z Luo, H Liu, E Metzakopian, HJ Fernandes, A Bassett, E Karran, BL Miller, A Fleming, DC Rubinsztein
Nature Communications 2019
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain
GJ Song, H Rahman, MK Jha, DP Gupta, SH Park, JH Kim, SH Lee, IK Lee, T Sim, YC Bae, WH Lee, K Suk
Frontiers in pharmacology 2019
Parkin interacting substrate zinc finger protein 746 is a pathological mediator in Parkinson’s disease
S Brahmachari, S Lee, S Kim, C Yuan, SS Karuppagounder, P Ge, R Shi, EJ Kim, A Liu, D Kim, S Quintin, H Jiang, M Kumar, SP Yun, TI Kam, X Mao, Y Lee, DA Swing, L Tessarollo, HS Ko, VL Dawson, TM Dawson
Brain 2019
Cell-Based Screen Using Amyloid Mimic β23 Expression Identifies Peucedanocoumarin III as a Novel Inhibitor of α-Synuclein and Huntingtin Aggregates
Sangwoo Ham, Hyojung Kim, Seojin Hwang, Hyunook Kang, Seung Pil Yun, Sangjune Kim, Donghoon Kim, Hyun Sook Kwon, Yun-Song Lee, MyoungLae Cho, Heung-Mook Shin, Heejung Choi, Ka Young Chung, Han Seok Ko, Gum Hwa Lee, Yunjong Lee
Molecules and Cells 2019
Regulation of α-synuclein by chaperones in mammalian cells
BM Burmann, JA Gerez, I Matečko-Burmann, S Campioni, P Kumari, D Ghosh, A Mazur, EE Aspholm, D Šulskis, M Wawrzyniuk, T Bock, A Schmidt, SG Rüdiger, R Riek, S Hiller
Nature 2019
Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity
GE Vázquez-Vélez, KA Gonzales, JP Revelli, CJ Adamski, FA Naini, A Bajić, E Craigen, R Richman, SM Heman-Ackah, MJ Wood, MW Rousseaux, HY Zoghbi
The Journal of neuroscience : the official journal of the Society for Neuroscience 2019
Kinase-Based Taming of Brain Microglia Toward Disease-Modifying Therapy
SH Lee, K Suk
Frontiers in cellular neuroscience 2018
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
SP Yun, TI Kam, N Panicker, SM Kim, Y Oh, JS Park, SH Kwon, YJ Park, SS Karuppagounder, H Park, S Kim, N Oh, NA Kim, S Lee, S Brahmachari, X Mao, JH Lee, M Kumar, D An, SU Kang, Y Lee, KC Lee, DH Na, D Kim, SH Lee, VV Roschke, SA Liddelow, Z Mari, BA Barres, VL Dawson, S Lee, TM Dawson, HS Ko
Nature Medicine 2018
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson’s disease mouse model
S Lee, S Kim, YJ Park, SP Yun, SH Kwon, D Kim, DY Kim, JS Shin, DJ Cho, GY Lee, HS Ju, HJ Yun, JH Park, WR Kim, EA Jung, S Lee, HS Ko
Human Molecular Genetics 2018
Graphene quantum dots prevent α-synucleinopathy in Parkinson’s disease
D Kim, JM Yoo, H Hwang, J Lee, SH Lee, SP Yun, MJ Park, MJ Lee, S Choi, SH Kwon, S Lee, SH Kwon, S Kim, YJ Park, M Kinoshita, YH Lee, S Shin, SR Paik, SJ Lee, S Lee, BH Hong, HS Ko
Nature Nanotechnology 2018
Tetracycline repurposing in neurodegeneration: focus on Parkinson’s disease
M Bortolanza, GC Nascimento, SB Socias, D Ploper, RN Chehín, R Raisman-Vozari, E Del-Bel
Journal of Neural Transmission 2018
Phosphotyrosine profiling of human cerebrospinal fluid
G Sathe, CH Na, S Renuse, A Madugundu, M Albert, A Moghekar, A Pandey
Clinical Proteomics 2018
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia–Reperfusion Injury: Involvement of c-Abl Activation
R Sun, Y Song, S Li, Z Ma, X Deng, Q Fu, R Qu, S Ma
Journal of Molecular Neuroscience 2018
Sensitivity and specificity of phospho-Ser129 α-synuclein monoclonal antibodies
V Delic, S Chandra, H Abdelmotilib, T Maltbie, S Wang, D Kem, HJ Scott, RN Underwood, Z Liu, LA Volpicelli-Daley, AB West
The Journal of Comparative Neurology 2018
Emerging Treatment Approaches for Parkinson’s Disease
TB Stoker, KM Torsney, RA Barker
Frontiers in neuroscience 2018
c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
Y Zhou, Y Yamamura, M Ogawa, R Tsuji, K Tsuchiya, J Kasahara, S Goto
Frontiers in pharmacology 2018
The emerging link between O-GlcNAcylation and neurological disorders
X Ma, H Li, Y He, J Hao
Cellular and Molecular Life Sciences 2017
Involvement of c-Abl Kinase in Microglial Activation of NLRP3 Inflammasome and Impairment in Autolysosomal System
V Lawana, N Singh, S Sarkar, A Charli, H Jin, V Anantharam, AG Kanthasamy, A Kanthasamy
Journal of Neuroimmune Pharmacology 2017
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
D Sulzer, RN Alcalay, F Garretti, L Cote, E Kanter, J Agin-Liebes, C Liong, C McMurtrey, WH Hildebrand, X Mao, VL Dawson, TM Dawson, C Oseroff, J Pham, J Sidney, MB Dillon, C Carpenter, D Weiskopf, E Phillips, S Mallal, B Peters, A Frazier, CS Arlehamn, A Sette
Nature 2017
The c-Abl inhibitor in Parkinson disease
ZH Zhou, YF Wu, X Wang, YZ Han
Neurological Sciences 2017
Mechanisms of Parkinson’s disease-related proteins in mediating secondary brain damage after cerebral ischemia
TH Kim, R Vemuganti
Journal of Cerebral Blood Flow & Metabolism 2017
Progress toward an integrated understanding of Parkinson’s disease
MW Rousseaux, JM Shulman, J Jankovic
F1000Research 2017
CRISPR-Cas9 Mediated Telomere Removal Leads to Mitochondrial Stress and Protein Aggregation
H Kim, S Ham, M Jo, G Lee, YS Lee, JH Shin, Y Lee
International journal of molecular sciences 2017
Ubiquitin and Parkinson's disease through the looking glass of genetics
H Walden, MM Muqit
Biochemical Journal 2017
c-Abl and Parkinson’s Disease: Mechanisms and Therapeutic Potential
S Brahmachari, SS Karuppagounder, P Ge, S Lee, VL Dawson, TM Dawson, HS Ko
Journal of Parkinson's disease 2017
Nilotinib – Differentiating the Hope from the Hype
RK Wyse, P Brundin, TB Sherer
Journal of Parkinson's disease 2016
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease
D Lindholm, DD Pham, A Cascone, O Eriksson, K Wennerberg, M Saarma
Frontiers in aging neuroscience 2016
Pulmonary surfactant: an immunological perspective
ZC Chroneos, Z Sever-Chroneos, VL Shepherd
Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 2009

← Previous 1 2 3 4 5 Next →

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 63 news outlets
Posted by 8 X users
Referenced in 1 patents
On 4 Facebook pages
Highlighted by 1 platforms
173 readers on Mendeley
1 readers on CiteULike
See more details